Peggy Sekula

Learn More
BACKGROUND Stevens-Johnson syndrome (SJS) and its severe form, toxic epidermal necrolysis (TEN), are rare but life-threatening cutaneous adverse reactions to drugs, especially to allopurinol, carbamazepine, lamotrigine, phenobarbital, phenytoine, sulfamethoxazole, oxicam and nevirapine. Recently, a strong association between carbamazepine and allopurinol(More)
BACKGROUND No treatment modality has been established as standard for patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. OBJECTIVE We sought to evaluate the effect of treatment on mortality in a large cohort of patients with Stevens-Johnson syndrome or toxic epidermal necrolysis. METHODS Data on therapy were retrospectively collected(More)
BACKGROUND Metabolites such as creatinine and urea are established kidney function markers. High-throughput metabolomic studies have not been reported in large general population samples spanning normal kidney function and chronic kidney disease (CKD). STUDY DESIGN Cross-sectional observational studies of the general population. SETTING AND PARTICIPANTS(More)
Stevens-Johnson syndrome and toxic epidermal necrolysis are severe cutaneous adverse reactions that are of major concern because of high mortality rates. On the basis of data collected in the RegiSCAR study, the aim was to assess risk factors (including modalities of patient management) for mortality, regardless of the cause, up to 1 year after the(More)
The purpose of this study was to evaluate the severity-of-illness score called SCORTEN with respect to its predictive ability and by using data obtained in the RegiSCAR study, the most comprehensive European registry of patients with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). For advanced comparisons, an auxiliary score (AS) was(More)
HLA-A*31:01 was reported to be associated with carbamazepine (CBZ)-induced severe cutaneous adverse reactions (SCAR), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We conducted an international study using consensus diagnosis criteria to enroll a total of 93(More)
BACKGROUND Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare but extremely severe cutaneous adverse drug reactions in which drug-specific associations with HLA-B alleles were described. OBJECTIVES To investigate genetic association at a genome-wide level on a large sample of SJS/TEN patients. METHODS We performed a genome wide(More)
BACKGROUND Generalized bullous fixed drug eruption (GBFDE) is a rare cutaneous adverse reaction to drugs, and may resemble Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), but is usually considered less severe. OBJECTIVES To compare the severity and mortality rate in cases of GBFDE and control cases of SJS or TEN of similar extent of(More)
Background / Objective Prior use of “lymphocyte transformation test” (LTT) suggested that it was less often positive in Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), than in other cutaneous reactions, with possible dependence on sampling date. We explored the possible role of inhibitory co-receptors in LTT, using well-defined groups of(More)